AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly Oncology, New CVRM and Fasenra in Respiratory. As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in R&D.
Pascal Soriot, Executive Director and Chief Executive Officer
Accelerating our strategic and financial development
AstraZeneca to acquire Alexion
We have
160
projects in our pipeline
Corporate Press Release